Therefore, one of the major challenges in immuno-oncology is understanding the mechanisms of resistance to ICI, to increase the proportion of patients benefiting from such treatment and to control treatment toxicity. This conservation of expression likely results from the dependence of cell-surface HLA-E expression on many distinct peptides, including the leader peptides of HLA-A, -B, or -C.

That way you always have a machine that is tailored to the demands and opportunities that you have right now.

We did not observe NKG2A expression on the surface of CD8 + T cells from the spleen, and few cells expressed PD-1 (∼0.

cells expressing HLA-Cw3 and HLA-Cw4 in the presence or absence of monalizumab (Mona) or obinutuzumab (Obz).mg/kg every 2 weeks) in combination with the approved dosage of cetuximab (400 mg/m 2 load then 250 mg/m 2 weekly) were explored. Thus, the anti-NKG2A mAb monalizumab can amplify the beneficial effects of other IO treatments, such as those promoting ADCC. Top panel: one representative dot plot showing the frequency of Flu tetramer positive (TMr +) CD8 + T cells after culture (n = 14).

This part was restricted to patients with recurrent and/or metastatic SCCHN who had received up to 2 prior systemic regimens for incurable SCCHN. The highest dose tested (10 mg/kg) was used for the phase II cohort expansion; the overall phase II study will include 40 patients. B) Semiquantitative analysis of HLA-E expression on formalin-fixed paraffin-embedded (FFPE) SCCHN samples (n = 65). The pool of A20 edited cells were stained with the anti-mouse-Qa-1 b antibody and the negative cells were sorted.

When normality was not reached, statistical significance between two paired samples populations was determined using Wilcoxon matched-pair signed rank test, statistical analyses for three or more groups. PBMCs were used to seed 24-well culture plates at a density of 2x10 6 cell/mL per well, in complete culture medium (IMDM + 1% penicillin-streptomycin and 10% human AB serum), at a final volume of 1 mL per well containing IL-15 at a final concentration of 10 ng/mL.